Researchers at the Perelman School of Medicine at the University of Pennsylvania, who led the study, revealed that lomitapide, a first-in-class microsomal triglyceride transfer protein (MTP) inhibitor, substantially and stably reduced LDL cholesterol (the "bad" cholesterol) in patients with the orphan disease homozygous familial hypercholesterolemia (HoFH).
What does MTTP stand for?
MTTP stands for Microsomal Triglyceride Transfer Protein
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of MTTP
We have 10 other meanings of MTTP in our Acronym Attic
- Mean Time to Mitigate
- Ministry to the Military (Church of God)
- Manipal the Talk.net
- Manitoba Therapeutic Touch Network (Canada)
- Ministry to the Nations (foundation)
- Music Through the Night
- Malignant Tracheobronchial Tree Obstructions (pulmonary medicine)
- Mean Time To Obsolescence
- Michael Todd True Organics Skincare
- Maximum Total Trihalomethane Potential
- Midwest Teacher Training Program (TEFL certificate program in Madison, Wisconsin)
- Moccasin-Type Tinea Pedis (dermatology)
- More to the Point
- Multi-service Tactics, Techniques and Procedures
- Monterey-Tippecanoe Township Public Library (Monterey, IN)
- Mean Time to React
- Mean Time to Reboot (computing)
- Mean Time To Recovery
- Mean Time To Release
- Mean Time To Repair
Samples in periodicals archive:
05) of hepatic protein levels of microsomal triglyceride transfer protein (MTP) (Figure 2A).
Those cholesterol-reducing drugs that followed statins were cholesteryl ester transporter protein (CETP) inhibitors, Niemann-Pick Cl-like 1 (NPC1L1) inhibitors, microsomal triglyceride transfer protein (MTTP) inhibitors, and acyl-CoA cholesterol acyltransferase (ACAT) inhibitors.
It is this domain with which microsomal triglyceride transfer protein (MTP) binds during apoB assembly.
a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug.
SLx-4090 is a first-in-class enterocyte-specific microsomal triglyceride transfer protein (MTP) inhibitor being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream) and obesity.
Hepatic and intestinal steatosis occur both in a-[beta]-lipoproteinemia (reflecting mutation of the microsomal triglyceride transfer protein, which allows apo B to associate physically with triglycerides in the liver and gut) and in homozygous hypo-[beta]-lipoproteinemia when mutations truncate apo B early in its sequence (2).
a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced top-line data from three separate Phase II trials involving its lead cholesterol management compound, AEGR-733, which is a microsomal triglyceride transfer protein (MTP) inhibitor.